Patents by Inventor Peter Winters
Peter Winters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12258750Abstract: A building panel is provided. The building panel includes an exterior wall portion, an interior wall portion, a pair of opposing sidewalls, a first end portion and an opposite second end portion. The pair of opposing sidewalls spacing apart the interior wall portion from the exterior wall portion to define a cavity therebetween. The exterior wall portion, the interior wall portion and the pair of opposing sidewalls are arcuate in shape to define the building panel. The first end portion has a slip lock slot extending between the pair of opposing sidewalls. The second end portion has a slip lock tab member extending between the pair of opposing sidewalls. The slip lock slot of the building panel is configured to receive the slip lock tab member of a second building panel to adjoin the first and second building panels in a continuous fashion.Type: GrantFiled: May 6, 2024Date of Patent: March 25, 2025Inventor: Peter Winters
-
Publication number: 20240287787Abstract: A building panel is provided. The building panel includes an exterior wall portion, an interior wall portion, a pair of opposing sidewalls, a first end portion and an opposite second end portion. The pair of opposing sidewalls spacing apart the interior wall portion from the exterior wall portion to define a cavity therebetween. The exterior wall portion, the interior wall portion and the pair of opposing sidewalls are arcuate in shape to define the building panel. The first end portion has a slip lock slot extending between the pair of opposing sidewalls. The second end portion has a slip lock tab member extending between the pair of opposing sidewalls. The slip lock slot of the building panel is configured to receive the slip lock tab member of a second building panel to adjoin the first and second building panels in a continuous fashion.Type: ApplicationFiled: May 6, 2024Publication date: August 29, 2024Inventor: Peter Winters
-
Patent number: 12006679Abstract: A building panel is provided. The building panel includes an exterior wall portion, an interior wall portion, a pair of opposing sidewalls, a first end portion and an opposite second end portion. The pair of opposing sidewalls spacing apart the interior wall portion from the exterior wall portion to define a cavity therebetween. The exterior wall portion, the interior wall portion and the pair of opposing sidewalls are arcuate in shape to define the building panel. The first end portion has a slip lock slot extending between the pair of opposing sidewalls. The second end portion has a slip lock tab member extending between the pair of opposing sidewalls. The slip lock slot of the building panel is configured to receive the slip lock tab member of a second building panel to adjoin the first and second building panels in a continuous fashion.Type: GrantFiled: June 16, 2022Date of Patent: June 11, 2024Inventor: Peter Winters
-
Publication number: 20240156816Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.Type: ApplicationFiled: December 15, 2023Publication date: May 16, 2024Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
-
Patent number: 11844800Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.Type: GrantFiled: October 30, 2020Date of Patent: December 19, 2023Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
-
Publication number: 20220403644Abstract: A building panel is provided. The building panel includes an exterior wall portion, an interior wall portion, a pair of opposing sidewalls, a first end portion and an opposite second end portion. The pair of opposing sidewalls spacing apart the interior wall portion from the exterior wall portion to define a cavity therebetween. The exterior wall portion, the interior wall portion and the pair of opposing sidewalls are arcuate in shape to define the building panel. The first end portion has a slip lock slot extending between the pair of opposing sidewalls. The second end portion has a slip lock tab member extending between the pair of opposing sidewalls. The slip lock slot of the building panel is configured to receive the slip lock tab member of a second building panel to adjoin the first and second building panels in a continuous fashion.Type: ApplicationFiled: June 16, 2022Publication date: December 22, 2022Inventor: Peter Winters
-
Publication number: 20220396777Abstract: In certain example embodiments, the invention provides a method of generating an ex vivo cell-based system comprising dissociating an original tissue sample obtained from a subject into a single cell population; determining an in vivo phenotype of the tissue sample by conducting single-cell RNA analysis on a first portion of the single cells; establishing an ex vivo cell-based system from a second portion of the single cells; and culturing the ex vivo cell-based system in a medium or conditions selected to maintain the in vivo phenotype. In some embodiments, the original tissue sample is a tumor tissue sample, such as a pancreatic ductal adenocarcinoma (PDAC) tumor sample.Type: ApplicationFiled: October 26, 2020Publication date: December 15, 2022Inventors: Alexander K. Shalek, Peter Winter, Andrew Navia, Srivatsan Raghavan, William Hahn, Andrew Aguirre, Brian Wolpin, Jennyfer Galvez-Reyes
-
Publication number: 20220184198Abstract: Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.Type: ApplicationFiled: January 24, 2022Publication date: June 16, 2022Applicant: Phibro Animal Health CorporationInventors: Peter Winter, Karen Brown, Michelle Mathiesen, Hailong Guo, Jeremy Griffel, Sam Christenberry, Meghan Quinn, Hector Cervantes, Bereket Zekarias
-
Publication number: 20210128557Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.Type: ApplicationFiled: October 30, 2020Publication date: May 6, 2021Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
-
Publication number: 20200311785Abstract: A system facilitates acquisition of virtual assets by obtaining information about a user and information about one or more computer applications associated with the user. When the user navigates a device to a catalog screen for virtual assets for computer applications, the system automatically presents to the user a filtered listing of applications for which purchasable virtual assets are available to the user that is filtered according to the information about the user and/or the information about one or more computer applications associated with the user. When the user selects an application on the filtered listing, the system automatically presents to the user a filtered catalog of purchasable virtual assets that are available to the user for the selected application that is filtered according to the information about the user and/or the information about one or more computer applications associated with the user.Type: ApplicationFiled: March 29, 2019Publication date: October 1, 2020Inventors: Sylvain Lagrand, Peter Winter, Rohan Kharbanda, Christopher Depizzol
-
Patent number: 10115851Abstract: Solar cell (11; 21; 31) having a dielectric coating arranged on a back side of the solar cell (11; 21; 31) which is at least partly covered by at least one planar contact (12; 22; 32), a boundary line (14; 24; 34) of the at least one planar contact (12; 22; 32) having at least one recess (16a, 16b; 26a, 26b, 26c), and method for producing same.Type: GrantFiled: October 14, 2011Date of Patent: October 30, 2018Assignees: Centrotherm Photovoltaics AG, RCT Solutions GMBHInventors: Andreas Teppe, Adolf Muenzer, Jan Schoene, Mathias Hein, Peter Winter
-
Publication number: 20130312823Abstract: Solar cell (11; 21; 31) having a dielectric coating arranged on a back side of the solar cell (11; 21; 31) which is at least partly covered by at least one planar contact (12; 22; 32), a boundary line (14; 24; 34) of the at least one planar contact (12; 22; 32) having at least one recess (16a, 16b; 26a, 26b, 26c), and method for producing same.Type: ApplicationFiled: October 14, 2011Publication date: November 28, 2013Inventors: Andreas Teppe, Adolf Muenzer, Jan Schoene, Mathias Hein, Peter Winter
-
Patent number: 7868023Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are as defined in the specification, as are A Z, Q, R1 and R2.Type: GrantFiled: April 3, 2008Date of Patent: January 11, 2011Assignee: Janssen Pharmaceutica NVInventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
-
Patent number: 7638056Abstract: The present invention provides a method of reducing the pathogen content of sewage sludge comprising (a) adding to the sludge an effective amount of a phosphorous-containing compound and (b) keeping the phosphorous-containing compound in contact with the sludge for a sufficient time to reduce the amount of pathogens present in the sludge by an amount equivalent to a logarithmic reduction of 2 or more.Type: GrantFiled: June 21, 2004Date of Patent: December 29, 2009Assignee: Rhodia OperationsInventors: Stephanie Edmunds, Douglas Paul Gilbert, Eric Robert Talbot, Manocher Asaadi, Peter Winter
-
Publication number: 20080255108Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.Type: ApplicationFiled: April 3, 2008Publication date: October 16, 2008Inventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
-
Patent number: 7385066Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.Type: GrantFiled: March 14, 2006Date of Patent: June 10, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
-
Publication number: 20080008993Abstract: The type III restriction enzyme EcoP15I is used to isolate from cDNA of an expressed gene a tag comprising more than 25 nucleotides and capable of identifying the expressed gene, wherein the 3? end of the tag is defined by a cleavage site of the type III restriction enzyme and the 5? end of the tag is defined by the cleavage site of another restriction enzyme that is closest to the 3? end of the cDNA of the expressed gene. The tag of the invention allows accurate quantitative gene expression analysis and rapid gene expression profiling in any organism for which no expressed sequence tag (EST) database is available.Type: ApplicationFiled: May 9, 2003Publication date: January 10, 2008Applicant: IWATE PREFECTURAL GOVERNMENTInventors: Guenter Kahl, Peter Winter, Detlev Krueger, Stefanie Reich, Hideo Matsumura, Ryohei Terauchi
-
Publication number: 20060243674Abstract: The present invention provides a method of reducing the pathogen content of sewage sludge comprising (a) adding to the sludge an effective amount of a phosphorous-containing compound and (b) keeping the phosphorous-containing compound in contact with the sludge for a sufficient time to reduce the amount of pathogens present in the sludge by an amount equivalent to a logarithmic reduction of 2 or more.Type: ApplicationFiled: June 21, 2004Publication date: November 2, 2006Inventors: Stephanie Edmunds, Douglas Gilbert, Eric Talbot, Manocher Assadi, Peter Winter
-
Publication number: 20060147881Abstract: A multi-functional dental post (11) has a transfer coping (13) head, for impression moulding, a core for crown or cap (21) support—with an optional extension filament (12), to fill a tooth root apex; the core can be milled from an integral transfer coping by CAD/CAM techniques.Type: ApplicationFiled: February 23, 2004Publication date: July 6, 2006Inventor: Peter Winter-Moore
-
Patent number: 5739326Abstract: Compounds of Formula I, and their N-oxides and agriculturally-suitable salts, are disclosed which are useful for controlling undesired vegetation ##STR1## wherein: X and Y are independently N or CH;Z is O, S(O).sub.n, NR.sup.7, C(.dbd.O), C(.dbd.S), C(.dbd.N--OR.sup.8), CH(OR.sup.9), or CR.sup.10 (R.sup.11);n is 0, 1 or 2; andR.sup.1 -R.sup.11 are as defined in the disclosure.Also disclosed are compositions containing the compounds of Formula I and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound of Formula I.Type: GrantFiled: December 3, 1996Date of Patent: April 14, 1998Assignee: E. I. du Pont de Nemours and CompanyInventors: Thomas Paul Selby, Michael Peter Winters